Preventive interventions can improve mental health outcomes in children, teens and young adults

May 18, 2021 – Offering interventions to young people in the general community can prevent the emergence of certain mental health disorders, according to the first comprehensive systematic review to address this question. The results appear in the May/June issue of Harvard Review of Psychiatry, which is published in the Lippincott portfolio by Wolters Kluwer.

“Preventive interventions for poor mental health outcomes in young people are feasible and appear to be effective,” according to the review by Gonzalo Salazar de Pablo, MD, and Andrea De Micheli, MD, of King’s College London, and colleagues. Evidence suggests that young people respond well to early interventions.

Universal and selective interventions reduce risk of most mental disorders

The researchers systematically reviewed decades of medical literature and found 295 studies in which individuals under 35 years old were randomly assigned to a mental health preventive intervention or a control group. Most studies examined psychoeducation (37 percent) or psychotherapy (28 percent), whereas 18 percent explored both and 17 percent involved other types of interventions.

Forty percent of the studies investigated universal interventions, which target a general population – for example, a high school assembly about alcohol use is a universal intervention. Other studies focused on selective interventions, which target symptom-free individuals who are considered at high risk of developing a mental disorder. Seventy percent of the studies were conducted in North America or Europe.

All told, 447,206 young individuals participated: 234,330 in intervention groups and 212,876 in control groups. The average age of the participants was 15 years, but they ranged from infants under 1 year to adults 34 years old.

The researchers combined the results of all studies using a statistical process called meta-analysis. Compared with control conditions, the 17 mental health disorders studied fell into three groups:

• Risk reduced by both universal and selective prevention measures: affective (mood) symptoms, alcohol use and its consequences, anxiety features, conduct problems, interpersonal violence, general psychological distress, posttraumatic stress disorder, tobacco use, and “other” emotional and behavioral problems
• Risk marginally reduced by both universal and selective prevention measures: attention-deficit/hyperactivity (ADHD) features, cannabis use, and externalizing behaviors (e.g., aggressive or antisocial)
• Risk not reduced by either universal or selective prevention measures: eating-related problems, impaired functioning, internalizing behaviors (e.g., fearful, anxious, or inhibited), and sleep-related problems

Psychoeducation interventions were particularly promising for ADHD features, affective symptoms, or interpersonal violence. Psychotherapy was most effective for anxiety features.

Even for interventions that showed some ability to prevent mental health problems, the effect sizes (the magnitude of the improvements) were small. However, Dr. Salazar de Pablo, Dr. De Micheli, and colleagues note: “Since these samples are typically young and not yet affected by psychiatric conditions, small effect sizes…can potentially translate into relevant benefits in the longer term—if the intervention is provided to enough individuals.”

Click here to read “Universal and Selective Interventions to Prevent Poor Mental Health Outcomes in Young People: Systematic Review and Meta-analysis.”

DOI: 10.1097/HRP.0000000000000294

###

About the Harvard Review of Psychiatry

The Harvard Review of Psychiatry is the authoritative source for scholarly reviews and perspectives on a diverse range of important topics in psychiatry. Founded by the Harvard Medical School Department of Psychiatry, the journal is peer reviewed and not industry sponsored. It is the property of Harvard University and is affiliated with all of the Departments of Psychiatry at the Harvard teaching hospitals. Articles encompass major issues in contemporary psychiatry, including neuroscience, epidemiology, psychopharmacology, psychotherapy, history of psychiatry, and ethics.

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.